In a bid to enhance Nigeria’s capacity to manufacture vaccines, medicines, and other essential health products, the European Union Delegation to Nigeria and the Economic Community of West African States (ECOWAS) convened a private sector meeting in Lagos. The initiative aims to bolster Nigeria’s health workforce, particularly in research and technical training, to ensure long-term sustainability in the sector.
Speaking at the event, Massimo De Luca, Head of Cooperation at the EU Delegation to Nigeria and ECOWAS, emphasized the EU’s commitment to forming sustainable partnerships that promote access to quality and affordable health products. He highlighted that these efforts complement the Nigerian government’s strategies through grants, technical assistance, and investment in local manufacturing.
The EU’s intervention is structured around five key areas: skills development through education and training, advancements in research and technology—including artificial intelligence and nanotechnology—digitalization of supply chain processes, improved procurement and distribution of medical products, and enhanced trade investments and customs facilitation. These strategies aim to create a more resilient and efficient health manufacturing ecosystem.
Through its initiative, TEI MAV+, the EU collaborates with African partners to address systemic barriers to local vaccine and medicine production. The EU has committed €18 million to MAV+, focusing on three core areas: skills development, resilient supply chains, and expanded access to finance and markets for locally produced goods. The EU will also strengthen research collaborations between Nigerian institutions and European research centers.
Furthermore, the EU’s digitalization efforts in the supply chain include supporting bioequivalence and bioavailability facilities, adherence to good manufacturing practices, and implementing tracking systems for pharmaceutical products. Access to finance for health-related businesses is also a major priority, with the Human Development Accelerator (HDX) financing instrument facilitating loans and investments, particularly for private-sector manufacturers involved in the production of Active Pharmaceutical Ingredients (APIs).
To ensure sustained impact, De Luca stated that the EU will maintain close coordination with its Member States and private sector stakeholders through bi-monthly Health Partners Meetings in Abuja. He also mentioned that new financing instruments, including equity investments, debt guarantees, and blended finance models, will be leveraged to encourage private-sector participation.
The EU’s investments in Nigeria’s health sector span various domains, including MAV+ (€18m for job creation and skill development), €4.2m support for public health institutes, €12.5m for sexual and reproductive health rights (SRHR), and €5.5m through UNICEF for supply chain digitalization. Additionally, €40m has been allocated to SRHR programs via UNICEF/UNFPA, €20m for the Safe Birth Africa project, €2.9m for digital health initiatives, and a €14m European Investment Bank (EIB) loan to Emzor Pharmaceuticals. The HDX initiative also serves as a dedicated financing instrument aimed at bolstering private-sector engagement in health product manufacturing.
By fostering these strategic partnerships and investments, the EU aims to position Nigeria as a hub for local vaccine and medicine production while ensuring sustainable development in the health sector.
Join Our Telegram Channel For Instant Notification
